Esperion Therapeutics

Esperion to Report First Quarter 2020 Financial Results May 6, 2020

Retrieved on: 
Giovedì, Aprile 30, 2020
Esperion Therapeutics, Low-density lipoprotein, NASDAQ, Ann Arbor, Michigan, Economy of the United States, Companies, Michigan

ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020.

Key Points: 
  • ANN ARBOR, Mich., April 30, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2020 financial results after the close of the U.S. financial markets on May 6, 2020.
  • Following the release, company management will host a webcast and conference call at 4:30 p.m.
  • ET to discuss financial results and business progress.
  • In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C.

Esperion to Participate in Fireside Chat at the 19th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Giovedì, Aprile 9, 2020
Telecommunications, Esperion Therapeutics, Low-density lipoprotein, GlobeNewswire, Fireside chats, Webcast, Service industries

ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020, at 12:50 p.m. Eastern Time.

Key Points: 
  • ANN ARBOR, Mich., April 09, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2020, at 12:50 p.m. Eastern Time.
  • A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/ .
  • Replay of the webcast will be archived on the Company's website for 90 days following the event.
  • In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated LDL-C.

Esperion Provides Lipid Management Franchise Updates; Reports Fourth Quarter and Full Year 2019 Financial Results

Retrieved on: 
Giovedì, Febbraio 27, 2020
Esperion Therapeutics, Ann Arbor, Michigan, Michigan

ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019.

Key Points: 
  • ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31, 2019.
  • 2019 was a precedent setting year for our Lipid Management Team highlighted by the January E.U.
  • This amount does not include U.S. product sales, for which Esperion will not provide revenue guidance in 2020, E.U.
  • Revenue was $1.0 million for the fourth quarter of 2019 and $148.4 million for the year ended December 31, 2019, compared to $0.0 million for the comparable periods in 2018.

Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Martedì, Gennaio 7, 2020
Medical specialties, Esperion Therapeutics, Bempedoic acid, Statin, Low-density lipoprotein, Medicine, Branches of biology

ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announcedthat president and chief executive officer,Tim M. Mayleben, will present at the 38thAnnualJ.P.

Key Points: 
  • ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announcedthat president and chief executive officer,Tim M. Mayleben, will present at the 38thAnnualJ.P.
  • Morgan Healthcare ConferenceinSan Francisco, CAonWednesday, January 15, 2020at12:00 p.m. Pacific Time/3:00 p.m. Eastern Time.
  • A live audio webcast of this event can be accessed on the investor relations section of the Esperion website at www.esperion.com/investors-media/events-presentations/ .
  • Bempedoic acid is our lead, non-statin, oral, once-daily, LDL-C lowering therapeutic candidate, currently under regulatory review by the FDA and EMA.

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

Retrieved on: 
Domenica, Novembre 17, 2019
Medicine, Clinical medicine, Health, Diabetes, Clinical research, Blood tests, Glucose, Glycated hemoglobin, Hemoglobins, Esperion Therapeutics, Bempedoic acid, Placebo

ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia.

Key Points: 
  • ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia.
  • The presentation highlighted that bempedoic acid reduced hemoglobin A1c (HbA1c) by 0.19% versus placebo in patients with diabetes (n=1,134) at 12 weeks.
  • The analysis also showed that patients on bempedoic acid had fewer instances of new-onset diabetes as well as hyperglycemia than those on placebo.
  • In addition, a poster, titled Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical Trials was presented by Maciej Banach, MD, PhD, FAHA, FESC.

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

Retrieved on: 
Mercoledì, Novembre 6, 2019
Health, Chemistry, Merck, Schering-Plough, Lactams, Esperion Therapeutics, Prescription Drug User Fee Act, Ezetimibe, Bempedoic acid, Tablet

ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.

Key Points: 
  • ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended September 30, 2019.
  • The Esperion Lipid Management Team continues to lay a strong and durable foundation for what we believe are highly anticipated approvals and launches of 2020 bempedoic acid and the bempedoic acid / ezetimibe combination tablet.
  • February 21, 2020 PDUFA target date for bempedoic acid and February 26, 2020 PDUFA target date for the bempedoic acid / ezetimibe combination tablet.
  • European Commission marketing authorisation decisions anticipated for both bempedoic acid and the bempedoic acid / ezetimibe combination tablet MAAs.

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

Retrieved on: 
Lunedì, Novembre 4, 2019
Lipids, Branches of biology, Medical specialties, Bempedoic acid, Esperion Therapeutics, Cardiology, Lipoproteins, Low-density lipoprotein, ATP citrate lyase, Cholesterol, LDL receptor

ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17,2019.

Key Points: 
  • ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American Heart Association (AHA) Scientific Sessions in Philadelphia on Sunday, November 17,2019.
  • Esperion completed its global, pivotal, Phase 3 clinical development program and announced positive cumulative results inOctober 2018.
  • The program included over 4,000 patients across five studies, four for bempedoic acid.
  • Inhibition of ATP Citrate Lyase (ACL) by bempedoic acid lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptor.

TSRL Announces the Appointments of Martha Farmer and Stephen Munk to Board of Directors, and Gregory Amidon as Chairman of the Board

Retrieved on: 
Giovedì, Ottobre 31, 2019
Esperion Therapeutics, Pfizer, Companies, Economy of the United States, Life sciences

ANN ARBOR, Mich., Oct. 30, 2019 /PRNewswire/ --TSRL, Inc., a preclinical accelerator, announces the appointments of Martha Farmer, PhD, and Stephen Munk, PhD to the Board of Directors, and Gregory Amidon, PhD, current board member, as Chairman.

Key Points: 
  • ANN ARBOR, Mich., Oct. 30, 2019 /PRNewswire/ --TSRL, Inc., a preclinical accelerator, announces the appointments of Martha Farmer, PhD, and Stephen Munk, PhD to the Board of Directors, and Gregory Amidon, PhD, current board member, as Chairman.
  • Elke Lipka, PhD, MBAwasnamed CEO in 2018 after serving as President and VP of Business Development for TSRL.
  • Lipka gained preclinical and early clinical drug development expertise at Parke Davis, Pfizer, and Esperion Therapeutics.
  • Martha Farmer and Stephen Munk are champions in their respective fields and committed to TSRL's mission to translate infectious disease product concepts into viable clinical candidates.

Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

Retrieved on: 
Martedì, Ottobre 29, 2019
Lipids, Branches of biology, Medical specialties, Cardiology, Bempedoic acid, Lipoproteins, Esperion Therapeutics, ATP citrate lyase, Low-density lipoprotein, Cholesterol, LDL receptor

ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open.

Key Points: 
  • ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets open.
  • Bempedoic acid has been observed to reduce hsCRP, a key marker of inflammation associated with cardiovascular disease.
  • Inhibition of ATP Citrate Lyase (ACL) by bempedoic acid lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptor.
  • 1 Esperion market research on file: research project interviewing 350 physicians.

OhsOwn LLC is Proud to Announce the Launch of the Mobile Application ESPR Calculator

Retrieved on: 
Giovedì, Ottobre 10, 2019
Articles, Economy, Free and open-source software, Mathematical software, Windows Calculator, Calculator, Analytics, Esperion Therapeutics, Computing

Not anymore with ESPR Calculator.

Key Points: 
  • Not anymore with ESPR Calculator.
  • Publicly available historical research data and statistical analyses were combined with practical real-world urologic experience to create an easy-to-understand percentile-based scoring system ranking overall erection size ESPR.
  • The app takes the inputted user parameters (length and girth), calculates an estimated total size, then compares this against the ESPR data to generate the final user ESPR score.
  • ESPR Calculator is completely private and secure with absolutely no advertisements, tracking, or analytics ability.